ABSTRACT Somatostatin in concentrations of 10-6 to 10-8 M inhibited basal release of thyrotropin releasing factor in organ culture of rat hypothalamus. Norepinephrine in doses of 10-4-10-6 M induced release of thyrotropin releasing factor which increased progressively with time and was temperature and dose dependent. This enhanced thyrotropin-releasing-factor release was inhibited by somatostatin at 10-6-10-8 M. The tetradecapeptide somatostatin, which is extensively distributed throughout the central nervous system, gastrointestinal tract, and pancreas (1-3), inhibits release of various hormones including growth hormone (4), thyrotropin (5), glucagon (6) and insulin (4). Somatostatin infusion lowers circulating thyrotropin in man (7), and passive immunization of rats with specific somatostatin antiserum increases basal and thyrotropin releasing factor (TRF)-stimulated thyrotropin secretion (8). These experiments imply an interrelationship between TRF and somatostatin and pituitary thyrotropin secretion. Potential local effects of somatostatin within the hypothalamus itself, either directly on peptide hormone secretion or via an action upon neurotransmitters, are equally likely and have not been critically examined.
approach has been to utilize short-term organ culture of rat hypothalamus as a model for delineating factors modulating in vitro release of TRF. We have found that somatostatin at 10-6 M-10-8 M inhibits basal release of TRF. Moreover, norepinephrine (NE) in doses of 10-4-10-6 M increases release of TRF, an effect which is not seen in the presence of somatosta- Male Sprague-Dawley rats (250 g body weight) were killed by decapitation at 10-11 a.m. After the brain was exposed by removal of the skull with sterile instruments, it was carefully placed in a sterile plastic petri dish which contained Ca2+, Mg2+-free Hanks' balanced salt solution, bacitracin (2.1 X 10-5 M), and glucose (6 mg/ml). Prior to use the dishes had been "gassed" with 5% C02/95% air. Dissection was performed in a laminar flow hood with sterile instruments at a plane 1 mm lateral to the midline and at a depth of 1 mm. The fragments were obtained from the area between the posterior margin of the optic chiasm and the anterior portion of the mammillary body. Microscopic examination (Fig. 2 ) demonstrated that the fragments included parts of the paraventricular, dorsomedial, ventromedial, suprachiasmatic, and arcuate nuclei, as well as the median eminence. Care was taken to ensure that the entire procedure from the time of death to initiation of the primary culture was performed within 1 min. From decapitation to placement into the petri dish took <40 sec. An additional 15-20 sec was required for hypothalamic dissection and transfer to the primary incubation medium for explanation. The explant was placed on a small piece of lens paper on a triangular wire mesh grid in a center well of an organ culture dish, and 0.5 ml of culture medium was added. The culture medium contained 88 vol of nutrient mixture F-12 with L-glutamine, 10 vol of heat-inactivated fetal calf serum, 1 vol of Hepes (10 mM in final concentration), 1 vol of Tricine (10 mM in final concentration), glucose (6 mg/ml in final concentration), and bacitracin (2.1 X 10-5 M in final concentration). The final pH was 7.3-7.5. The hypothalami were cultured in groups of three and maintained in a humidified incubator overnight (24 hr) at 370 in an atmosphere of 5% C02/95% air. The use of heat-inactivated fetal calf serum and bacitracin served to prevent enzymatic degradation of TRF (12, 13) and represented a major change from published techniques (14, 15) . At the conclusion of the primary culture a preincubation was carried out for 10 mg/ml (approximately 3-fold greater than the normal concentration in order to facilitate longer cell viability), the addition of bacitracin (2.1 X 10-5 M, pH 7.4) to prevent enzymatic breakdown of TRF, and the use of potassium at twice the normal level in an attempt to maintain the intracellular potassium concentration. Both preincubations and experimental incubations were done at 37°in an atmosphere of 5% C02/95% air. Measurements of glucose concentrations in the organ culture medium were performed by utilizing the glucose oxidase method (16) . TRF release was quantitated by assay of the medium with a highly specific, sensitive radioimmunoassay for TRF (17) (18) (19) (20) . Statistical significance for all experiments in this study was determined by the Student t test. TRF content was determined by a modification of published methods (21, 22) . Our procedure has been described in detail (17) (18) (19) (20) . In essence three hypothalami, the contents of one sample dish, were homogenized in 1 ml of ice cold methanol utilizing a PotterElvehjem apparatus by 10 up-and-down strokes of the pestle rotating at 2.5 rpm, were suspended in ice cold (40) 90% methanol (0.5 ml of homogenate per 2 ml), and were centrifuged at 1000 X g for 30 min. The resultant supernatant was dried with an air stream while immersed in a water bath at 600, stored at -200, and dissolved in 0.5 ml of phosphate/sodium chloride buffer (0.25% bovine serum albumin/0.15 M NaCl/ 0.01 M phosphate, pH 7.5) prior to assay. With this procedure the mean yield of exogenously added cold TRF in six experiments was 99.7%.
RESULTS
Authenticity of radioimmunoassayable TRF was indicated by immunologic, chromatographic, and enzymatic criteria. Immunologically, there was virtual absence of crossreaction with closely related TRF analogs (Table 1) . We assessed the extent of crossreaction of a given analog with TRF antibody by comparing the relative concentration of the compound with that Table 1 <Glu-His-Pro-OH; <Glu-His-Gly-NH2; <Glu-His-OCH3; body reaction (Fig. 1 top) . In addition, there was parallelism of dilutions of putative TRF present in hypothalamic extract and TRF added to the experimental media. The appearance of parallelism was confirmed by logit log transformation of the data and comparison of the resultant regression lines by analysis by the F test (23, 24) . Chromatographically (Fig. 1 middle) (Fig. 1 bottom) .
The general validity of the organ culture system was indicated by (a) good preservation of the fine structure of the incubated hypothalamus (Fig. 2) and satisfactory replication of dissection of hypothalami as assessed by histological examination; (b) reproducibility of TRF content in dissected hypothalami to within 9.9% for 11 experiments involving 38 hypothalamic cultures (coefficient of variation; see Table 2 Fig. 3 ). Addition of NE, alone or in combination with dithioerythritol to inhibit oxidation of NE, failed to alter enzymatic degradation of TRF at 370 in the presence of rat plasma, suggesting that the effect of NE does not involve merely stabilization of TRF. Addition of somatostatin alone at concentrations of 10-6 M, 10-7 M, and 10-8 M resulted in significant inhibition of TRF release. There was inhibition to 47.1% of control at 10-6 M somatostatin (P < 0.02), to 53.7% of control at 10-7 M (P < 0.001), and to 37.3% of control at 10-8 M (P < 0.02) (Fig. 4) . To ascertain if somatostatin was also capable of inhibiting neurotransmitter-mediated release of TRF, we utilized the model of NE-induced TRF release. For these studies 10-4 M NE was selected to achieve a near maximal response. When incubated with 10-7 M and 10-8 M somatostatin, the TRF response to NE appeared to be completely abolished (P < 0.05) (Fig. 5 ).
DISCUSSION
Our application of the organ culture technique to study TRF release was stimulated by prior reports that fragments of hypothalamus and median eminence from mink (26) , guinea pig (15, 27) , and rat (26, 28) (29) . The level of TRF released in the combined presence of NE and somatostatin was similar to the basal TRF release in this system (control in Fig. 5 ). There are several potential explanations for this finding. Conceivably, responsiveness to NE is actually retained in the presence of somatostatin, and the apparent absence of a response to NE reflects a depression in the basal response. Alternatively one could postulate the converse-i.e., NE blocks the inhibitory effects of somatostatin on basal secretion which is itself unchanged. However, further studies on the interaction of somatostatin and NE and on the Somatostatin and TRF are both widely distributed throughout the central nervous system, often in similar locations (1, 3, (31) (32) (33) 7- its responsiveness to levels of somatostatin of the order of 10-8 M-i.e., similar to or possibly somewhat less than those that we and others have found in the hypothalamus and median eminence (3) . Nevertheless our in vitro observations clearly cannot be extrapolated to the in vivo situation without further studies.
